Other Notes Note 17: Related Party Transactions Ultimate controlling entity and subsidiaries The ultimate controlling entity is CSL Limited, otherwise described as the parent company. The following table lists the Group’s material subsidiaries including those acquired in connection with the acquisition of CSL Vifor during the year ended 30 June 2023 (Note 2). Percentage owned (%) Company Country of Incorporation 2023 2022 CSL Limited Australia Subsidiaries of CSL Limited: CSL Innovation Pty Ltd Australia 100 100 CSL Behring (Australia) Pty Ltd Australia 100 100 CSL Behring LLC USA 100 100 CSL Plasma Inc USA 100 100 CSL Behring GmbH Germany 100 100 CSL Behring AG Switzerland 100 100 CSL Behring Lengnau AG Switzerland 100 100 CSLB Holdings Inc USA 100 100 CSL Finance Plc UK 100 100 CSL Behring Holdings Limited UK 100 100 CSL Behring (Holdings) Pty Ltd UK 100 100 CSL Finance Pty Ltd Australia 100 100 Seqirus Pty Ltd Australia 100 100 Seqirus UK Limited UK 100 100 Seqirus Vaccines Limited UK 100 100 Seqirus USA Inc USA 100 100 Seqirus Inc USA 100 100 Vifor Pharma Participations Ltd24 Switzerland 100 – Vifor (International) Ltd Switzerland 100 – Vifor Fresenius Medical Care Renal Pharma Ltd Switzerland 55 – Related party transactions All transactions with subsidiaries have been eliminated on consolidation. 24 Vifor Pharma Ltd was merged into Vifor Pharma Participations Ltd effective 14 June 2023. CSL Limited Annual Report 2022/23 151
RkJQdWJsaXNoZXIy MjE2NDg3